Status:
TERMINATED
Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer
Lead Sponsor:
Hellenic Oncology Research Group
Collaborating Sponsors:
University Hospital of Crete
Conditions:
Non-Small-Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a prospective pilot phase II trial, in patients with wet stage IIIb and IV NSCLC using chemotherapy regimens which will be defined according to the pharmacogenomic profile (tumoral expression ...
Detailed Description
Advanced stage NSCLC is essentially a fatal disease and treatment is mainly palliative. Systemic cisplatin-based chemotherapy remains the mainstream for the treatment of advanced non-small cell lung c...
Eligibility Criteria
Inclusion
- Patients with histologically proven Stage IV and Stage III (with malignant pleural or pericardial effusion) squamous or adenocarcinoma carcinomas of the lung
- Adequate Formalin Fixed Paraffin Embedded tumor sample provided for molecular analysis
- No previous anticancer treatment for metastatic/advanced disease. Patients who received prior adjuvant chemotherapy are eligible if they have remained free of disease for at least 6 months after the completion of adjuvant therapy.
- Age above 18 years
- Performance status (ECOG) 0-2
- Life expectancy \>= 3 months
- Effective contraception for both male and female subjects if the risk of conception exists
- Adequate hematologic parameters (absolute neutrophil count \>= 1.5x109/L and platelets \>= 100x109/L), creatinine (GFR\>= 60ml/min) and total bilirubin \< 1.5 times the upper limit of normal; aspartate and alanine aminotransferase \< 2,5 times the upper limit of normal
- All patients will have to sign written informed consent in order to participate in the study
Exclusion
- Patients with non-squamous tumors who have no contradiction for administration of bevacizumab
- Active infection or malnutrition (loss of more than 20% of the body weight)
- Known hypersensitivity reaction to any of the component of the treatment
- Concurrent or previous chronic systemic immune therapy
- Pregnancy (absence to be confirmed by ß-HCG test) or lactation period
- Known alcohol/drug abuse
- Legal incapacity or limited legal capacity
- Medical or psychological condition which in the opinion of the investigator would not permit the subject to complete the study or sign meaningful informed consent
- A second primary tumor other than non-melanoma skin cancer or in situ cervical carcinoma
- Previous radiotherapy to the target lesions. Patients treated with palliative radiotherapy had to have measurable metastatic disease outside the irradiation fields
- Patients with severe cardiac dysfunction, unstable angina petrosis, or high risk of uncontrolled arrhythmia
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT00705549
Start Date
February 1 2008
End Date
September 1 2011
Last Update
February 13 2013
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
University General Hospital of Alexandroupolis, Dept. of Medical Oncology
Alexandroupoli, Greece
2
"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine
Athens, Greece
3
401 Military Hospital, Medical Oncology Unit
Athens, Greece
4
Air Forces Military Hospital, Dep of Medical Oncology
Athens, Greece